- Home
- ZWS vs RARE Comparison
ZWS vs RARE Comparison
Compare ZWS & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZWS
- RARE
- Stock Information
- Founded
- ZWS 1892
- RARE 2010
- Country
- ZWS United States
- RARE United States
- Employees
- ZWS N/A
- RARE N/A
- Industry
- ZWS Industrial Machinery/Components
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- ZWS Industrials
- RARE Health Care
- Exchange
- ZWS Nasdaq
- RARE Nasdaq
- Market Cap
- ZWS 6.1B
- RARE 5.2B
- IPO Year
- ZWS 2012
- RARE 2014
- Fundamental
- Price
- ZWS $38.84
- RARE $40.89
- Analyst Decision
- ZWS Buy
- RARE Strong Buy
- Analyst Count
- ZWS 6
- RARE 15
- Target Price
- ZWS $38.50
- RARE $92.00
- AVG Volume (30 Days)
- ZWS 940.4K
- RARE 1.0M
- Earning Date
- ZWS 02-04-2025
- RARE 02-13-2025
- Dividend Yield
- ZWS 0.93%
- RARE N/A
- EPS Growth
- ZWS 24.05
- RARE N/A
- EPS
- ZWS 0.79
- RARE N/A
- Revenue
- ZWS $1,552,600,000.00
- RARE $522,745,000.00
- Revenue This Year
- ZWS $3.10
- RARE $26.70
- Revenue Next Year
- ZWS $3.74
- RARE $19.02
- P/E Ratio
- ZWS $49.45
- RARE N/A
- Revenue Growth
- ZWS 2.55
- RARE 27.44
- 52 Week Low
- ZWS $28.25
- RARE $37.02
- 52 Week High
- ZWS $41.15
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- ZWS 59.20
- RARE 40.43
- Support Level
- ZWS $35.75
- RARE $39.99
- Resistance Level
- ZWS $37.63
- RARE $44.52
- Average True Range (ATR)
- ZWS 0.78
- RARE 2.18
- MACD
- ZWS 0.23
- RARE -0.03
- Stochastic Oscillator
- ZWS 92.24
- RARE 17.75
About ZWS Zurn Elkay Water Solutions Corporation
Zurn Elkay Water Solutions Corp designs procure, manufactures, and markets a range of clean water solutions for drinking water, hygiene, and sustainable water management. The Zurn Elkay product portfolio includes professional-grade water control and safety, water distribution and drainage, drinking water, finish plumbing, hygienic, environmental and site works products for public and private spaces.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.